People · Operator
Named in public records as an officer, director or promoter · active 2009–2020 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Intarcia Therapeutics, Inc | — | Biotechnology | Growth/Late | $1.2B | $8.4B | 2012 |
| Synlogic, Inc. | — | Biotechnology | Series C | $186.5M | $3.3B | 2014 |
| Reneo Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $159.4M | $519.3M | 2017 |
| Mirum Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $138.5M | $347.9M | 2018 |
| Akouos, Inc. | — | Biotechnology | Series D+ | $137.7M | $4.3B | 2017 |
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2015 |
| Liquidia Technologies Inc | — | Biotechnology | Series B | $86.7M | $890.0M | 2009 |
| Senti Biosciences, Inc. | — | Biotechnology | Series B | $77.0M | $221.8M | 2018 |
| Synlogic, LLC | — | Biotechnology | Series B | $31.0M | $679.3M | 2016 |
| Envisia Therapeutics, Inc. | — | Biotechnology | Series A | $14.7M | $365.8M | 2015 |
| Curzion Pharmaceuticals, Inc. | — | Pharmaceuticals | Seed | $3.5M | $133.1M | 2019 |
Ed Mathers at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Ed Mathers on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 3 | 12 |
| Michael Grey | 3 | 10 |
| Peter Barrett | 2 | 18 |
| Stephen Bloch | 2 | 15 |
| Chau Khuong | 2 | 9 |
| Niall O'Donnell | 2 | 7 |
| Lewis Geffen | 2 | 6 |
| Seth Rudnick | 2 | 5 |
| ANKIT MAHADEVIA | 2 | 4 |
| Johan Kordel | 2 | 4 |
| Neal Fowler | 2 | 4 |
| Susan Dube | 2 | 3 |
| Edward T. Mathers | 2 | 3 |
| Jose Carlos Gutierrez-Ramos | 2 | 2 |
| Michael G. Grey | 2 | 2 |
| Michael Williams | 1 | 27 |
| Bryan Roberts | 1 | 18 |
| Michael Powell | 1 | 14 |
| Corey Goodman | 1 | 13 |
| Patrick Heron | 1 | 11 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.